Skip to content. | Skip to navigation

National Cancer Institute U.S. National Institutes of Health


Personal tools

You are here: Home / Biomarkers / HOXA9



This biomarker is also known as:
  • homeobox protein Hox-1G,
  • homeobox protein Hox-A9,
  • P31269,
  • homeobox A9,
  • Homeobox protein Hox-1G,
  • homeodomain protein HOXA9,
  • homeo box A9,
  • HOX1.7,
  • HOX1G,
  • HOX1,
  • ABD-B,

View in BioMuta


HOXA9 is a sequence-specific transcription factor. It is a member of the homeobox gene family. These transcription factors are spatially and temporally regulated during embryonic development. HOXA9 is part of the A cluster on chromosome 7 and encodes a DNA-binding transcription factor which may regulate gene expression, morphogenesis, and differentiation. Read-through transcription exists between this gene and the upstream homeobox A10 (HOXA10) gene.


QA State: Curated
Type: Protein
Short Name:


There are no datasets associated with this biomarker.


The following organs have data associated with this biomarker…

Head & neck, NOS


Phase: One
QA State: Curated


HOXA9 and NID2 have been identified as novel differentially methylated genes in oral squamous cell carcinoma. These genes were also shown to have significantly higher methylation levels in tumor than normal oral mucosa, as seen by ROC analysis of head and neck squamous cell carcinoma samples.

Performance Comment

HOXA9 and NID2 are promising oral squamous cell carcinoma biomarkers that should be studied on tissue, saliva and serum from larger cohorts. HOXA9 and NID2 were chosen for further study because they were the only candidate genes that had an AUC value equal to or higher than 0.75, and 100% specificity and sensitivity higher than 70%.



Phase: Two
QA State: Under Review


DNA methylation of HOXA9 has been found to be associated with ovarian cancer.

Performance Comment

HOXA9 was one of 50 tumor vasculature-associated genes with transmembrane or secreted protein products identified through expression profiling of ovarian cancer vascular cells. These 50 tumor vascular markers (TVMs) also had low or no expression in normal tissues. HOXA9 was not in the group of 13 selected for further validation.



Phase: One
QA State: Under Review


Performance Comment


This biomarker is currently being annotated or is under review. You must be logged in or do not have permission to view any additional information. Contact Heather Kincaid at if you should have access to this biomarker.

New Funding Opportunity: Biomarker Development Laboratories for the Early Detection Network: Applications Due May 23

Update: Pre-application webinar information now available.

The National Cancer Institute's Division of Cancer Prevention has released a new funding opportunity to solicit organ-specific applications for Biomarker Developmental Laboratories (BDLs), one of the four scientific units of the recently funded Early Detection Research Network (EDRN). The EDRN is a national infrastructure funded to discover, develop, and validate biomarkers for risk assessment, detection, and molecular diagnosis and prognosis of early cancer. BDLs are responsible for the discovery, development, characterization, and testing of new, or the refinement of existing, biomarkers and biomarker assays for risk assessment, detection, and molecular diagnosis and prognosis of cancers.

The existing BDLs are primarily focused on ovary and gastrointestinal cancers. The proposed BDLs (to be supported under this funding opportunity) should be focused on one or more of the following cancers: breast, prostate and other genitourinary organs, or lung. In addition, cancers with rapidly rising incidence rates, e.g., endometrial, hepatocellular, kidney, thyroid, oropharyngeal cancers, and/or cancers with unique etiology, e.g., mesothelioma, will be considered.

The newly funded units of the Early Detection Research Network will be announced later in April. Successful applicants have already been notified. Those researchers who were not successful during the last round of applications are encouraged to apply to this opportunity.